REG - Ergomed plc - Total Voting Rights & Block Listing Return

ErgomedAnnouncement

01/07/2019 07:05

RNS Number : 9342D
Ergomed plc
01 July 2019
 


 PRESS RELEASE
 
 
Date: 1 July 2019
Ergomed plc
 
TOTAL VOTING RIGHTS AND BLOCK LISTING RETURN
 
 
Total Voting Rights
 
In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules (DTRs), Ergomed plc (the "Company") announces the following information.
The Company's issued share capital as at 30 June 2019 consisted of 46,717,412 ordinary shares of 1p each, none of which were held in treasury.  Each ordinary share in the capital of the Company carries one voting right. 
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.
 
 
Block Listing Six Monthly Return
 
 



Name of applicant:


Ergomed plc




Name of scheme:


Ergomed plc Long Term Incentive Plan




Period of return:


From:


1 January 2019


To:


30 June 2019




Balance of unallotted securities under scheme(s) from previous return:


1,745,000




Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):


nil




Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):


542,164




Equals:  Balance under scheme(s) not yet issued/allotted at end of period:


1,202,836




Number and class of securities originally admitted and the date of admission


1,800,000 ordinary shares of 1p each - 2 July 2018




Total number of securities in issue at the end of the period


46,717,412 ordinary shares of 1p each










 



Name of contact:


Nick Blech - Deputy CFO




Telephone number of contact:


+44 (0)7768 547372



 
 Enquiries:



Ergomed plc


Tel: +44 (0) 1483 503205




Richard Barfield (Chief Financial Officer)
 
 


















Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Freddie Barnfield (Nominated Adviser)








James Black (Broker)
 








Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Mary-Jane Elliott
Matthew Neal / Olivia Manser
 
 


ergomed@consilium-comms.com














MC-Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke







 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSDFEFSFUSELM